Clinical Trials Sponsored by Sutro Biopharma, Inc.

Total 332 results

Civi Biopharma, Inc.

Completed

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Hypercholesterolemia

United States
ReveraGen BioPharma, Inc.

Withdrawn

Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

Pediatric Ulcerative Colitis
Therapure Biopharma Inc

Unknown

Study of PlasmaCap IG in Adults and Children With PIDD

Primary Immune Deficiency Diseases (PIDD)

United States, Canada
Acrotech Biopharma Inc.

Withdrawn

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Non-Small Cell Lung Cancer
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

B-cell Lymphoma | Hodgkin's Lymphoma | Relapsed or Refractory Lymphoproliferative Malignancies | Peripheral T-cell Lymphoma | Waldenstrom's Macroglobulinemia

United States
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

Breast Cancer | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Human Mammary Carcinoma

France, United States, Czechia, Hungary
Alios Biopharma Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Chronic Hepatitis C

New Zealand, Moldova, Republic of, Mauritius, United Kingdom
Alios Biopharma Inc.

Completed

A Study of ALS-008176 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

United States, Taiwan, Australia, Canada, United Kingdom, Colombia, France, New Zealand, Japan, South Africa, Chile, Panama, Romania, Thailand
Alios Biopharma Inc.

Completed

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Influenza in Humans

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

Australia, Singapore, United States, New Zealand, Taiwan
Alios Biopharma Inc.

Completed

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

Influenza

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Respiratory Syncytial Virus Infections

United Kingdom
S1 Biopharma, Inc.

Completed

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety (PURPLE)

Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined) | Sexual Interest/Arousal Disorder (DSM-5 Defined)

United States
ARCA Biopharma, Inc.

Completed

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

Catheters, Indwelling

United States
Ambrilia Biopharma, Inc.

Completed

Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

Belarus, Hungary, Serbia, Ukraine, Romania, Slovakia
ARCA Biopharma, Inc.

Suspended

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

Colon Cancer

United States
ARCA Biopharma, Inc.

Terminated

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

Acute Ischemic Stroke

United States, Canada
ARCA Biopharma, Inc.

Completed

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

Arterial Occlusive Diseases

United States
BioPharmX, Inc.

Completed

A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness

Fibrocystic Breast Condition (FBC)

United States, Canada
BioPharmX, Inc.

Completed

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Acne Vulgaris

United States
Benitec Biopharma, Inc.

Recruiting

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Oculopharyngeal Muscular Dystrophy

United States
Landos Biopharma Inc.

Recruiting

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Italy, Poland
Artax Biopharma Inc

Recruiting

Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United Kingdom
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
XEME Biopharma Inc.

Not yet recruiting

Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma

Follicular Lymphoma

United States
Acrotech Biopharma Inc.

Completed

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Atopic Dermatitis

United States
Aytu BioPharma, Inc.

Withdrawn

Respiratory COVID-19: A Randomized, Sham-Controlled Study

Acute Respiratory Distress Syndrome | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome

Spain
AiViva BioPharma, Inc.

Withdrawn

A Safety and Efficacy Study to Evaluate Rosacea

Papulopustular Rosacea

United States
AiViva BioPharma, Inc.

Completed

Effect of Intravitreally Administered AIV007 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

United States
Landos Biopharma Inc.

Completed

Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers

Ulcerative Colitis

Australia
Fountain Biopharma Inc.

Completed

An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis

Atopic Dermatitis

Taiwan
Matinas Biopharma, Inc

Completed

A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules (PK/PD)

Hypertriglyceridemia

Canada
Civi Biopharma, Inc.

Completed

A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level

Hypercholesterolemia

United Kingdom
Ansun Biopharma, Inc.

Withdrawn

DAS181 for STOP COVID-19

COVID-19

Italy
Ansun Biopharma, Inc.

Unknown

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) (STOP-Flu)

Influenza Infection | SAD-RV Infection and COVID-19

China
Janssen BioPharma, Inc.

Completed

A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants

Healthy

United Kingdom
Acrotech Biopharma Inc.

Completed

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry (COMPLETE)

Peripheral T-cell Lymphoma

United States
Acrotech Biopharma Inc.

Completed

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Peripheral T-cell Lymphoma

United States
Acrotech Biopharma Inc.

Completed

Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer

Advanced Cancer

Spain
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PROPEL)

Peripheral T-cell Lymphoma

United States, United Kingdom, Canada, France, Italy, Belgium
Acrotech Biopharma Inc.

Completed

PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation

Multiple Myeloma

United States
Acrotech Biopharma Inc.

Completed

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

Malignant Melanoma

United States
Alios Biopharma Inc.

Completed

A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Moldova, Republic of, New Zealand, Thailand, Ukraine
Oncolys BioPharma Inc

Unknown

A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Solid Tumor

United States
Micelle BioPharma Inc

Unknown

Dose-Finding Study of SC411 in Children With Sickle Cell Disease (SCOT)

Sickle Cell Disease

United States
Alios Biopharma Inc.

Completed

Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers

Respiratory Syncytial Virus Infections

France
Alios Biopharma Inc.

Terminated

A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Hepatitis C

Belgium
Alios Biopharma Inc.

Withdrawn

A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects

Hepatitis B, Chronic
Ansun Biopharma, Inc.

Completed

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (PIV)

Parainfluenza

United States

3

Subscribe